Phar­maEssen­tia takes Besre­mi rare blood can­cer mes­sage to con­sumers

Phar­maEssen­tia’s first prod­uct Besre­mi is the on­ly first-line treat­ment ap­proved for poly­cythemia ve­ra (PV). Now mar­ket­ed for more than a year, the drug­mak­er is ready to take its mes­sage di­rect­ly to con­sumers.

The “What Counts” cam­paign is fo­cused on in­creas­ing PV ed­u­ca­tion around the lit­er­al blood counts im­por­tant in man­ag­ing PV, but al­so the more im­por­tant things in life that count when liv­ing with the rare, life-threat­en­ing blood can­cer. PV caus­es over­pro­duc­tion of blood cells putting pa­tients at risk for blood clots, stroke and heart at­tack.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER